BioNexus Gene Lab Corp.
BGLCNASDAQHealthcare● Active
$2.19
$-0.01(-0.45%)
Market Cap$4405448
P/E Ratio—
52W High$15.6
52W Low$1.92
BioNexus Gene Lab Corp. (BGLC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BGLC · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.42M | $9.51M | $9.77M | $10.93M | $13.36M |
| Cost of Revenue | $6.34M | $8.22M | $8.44M | $9.67M | $11.17M |
| Gross Profit | $1.09M | $1.29M | $1.33M | $1.26M | $2.19M |
| Gross Margin %(computed) | 14.62% | 13.56% | 13.61% | 11.52% | 16.42% |
| Operating Expenses | |||||
| R&D Expenses | $0.05M | $0.05M | $0.05M | $0.00M | $0.00M |
| G&A Expenses | $2.33M | $1.97M | $2.44M | $1.73M | $1.20M |
| Total Operating Expenses | $4.24M | $2.86M | $3.92M | $1.55M | $1.14M |
| Operating Income | ($3.16M) | ($1.57M) | ($2.59M) | ($0.29M) | $1.06M |
| Operating Margin %(computed) | -42.54% | -16.55% | -26.54% | -2.66% | 7.90% |
| Interest Income | $0.08M | $0.15M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.02M | $0.02M | $0.01M | $0.01M | $0.01M |
| Income Before Tax | ($2.98M) | ($1.59M) | ($2.61M) | ($0.30M) | $1.04M |
| Income Tax Expense | $0.00M | $0.00M | $0.02M | $0.05M | $0.29M |
| Net Income | ($2.98M) | ($1.60M) | ($2.63M) | ($0.36M) | $0.75M |
| Net Margin %(computed) | -40.20% | -16.81% | -26.91% | -3.26% | 5.62% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.61 | $-0.90 | $-1.53 | $-0.25 | $0.53 |
| Wtd Avg Shares | 1.86M | 1.78M | 1.72M | 1.44M | 1.43M |
| EBITDA | ($2.80M) | ($1.42M) | ($2.49M) | ($0.19M) | $1.16M |
| EBITDA Margin %(computed) | -37.67% | -14.94% | -25.43% | -1.70% | 8.71% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more BioNexus Gene Lab Corp. data
About BioNexus Gene Lab Corp. (BGLC) Income Statement
BioNexus Gene Lab Corp. (BGLC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BGLC reported revenue of $0.01B, gross profit of $0.00B (gross margin 14.62%), and net income of ($0.00B) — a net profit margin of -40.20%.
Frequently asked questions
BGLC · 4 questionsBioNexus Gene Lab Corp. (BGLC) reported revenue of $0.01B for 2025, down 21.9% year-over-year.
BGLC revenueBGLC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08